If you don't see a role posted...
Adaptive BiotechnologiesSalary not specified
- Full Time
- Mid-level (3 to 4 years), Senior (5 to 8 years)
Adaptive Biotechnologies
Decodes immune cell genetic information for diagnostics
About Adaptive Biotechnologies
Adaptive Biotechnologies focuses on using the immune system to improve disease diagnosis and treatment. The company decodes genetic information from immune cell receptors, which are essential for the immune system's ability to identify and respond to diseases. One of their key projects is the ImmuneRACE study, which analyzes blood samples and swabs from participants to understand the immune response to COVID-19. This research aims to enhance diagnostics, treatments, and vaccines for the virus. Adaptive Biotechnologies uses advanced data algorithms to analyze immune cell genetics and generates revenue through partnerships with pharmaceutical companies, licensing technology, and offering diagnostic services. Their goal is to leverage immune system data to advance healthcare and develop effective therapies for various diseases.
Seattle, WashingtonHeadquarters
2009Year Founded
$395.8MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
501-1,000Employees
Benefits
Company Equity
Performance Bonus
Risks
Competition from startups like Adaptive could divert focus from core biotechnology efforts.
Regulatory hurdles may delay EndoSound partnership's endoscopy device development.
BeiGene collaboration success depends on the progress of their pipeline treatments.
Differentiation
Adaptive Biotechnologies leverages immune system data for advanced diagnostics and treatments.
Their clonoSEQ® assay is FDA-authorized for minimal residual disease detection in blood cancers.
The ImmuneRACE study enhances understanding of immune responses to COVID-19.
Upsides
Collaboration with BeiGene expands market reach for clonoSEQ® in lymphoid malignancies.
EndoSound partnership highlights potential in innovative gastroenterology diagnostics.
Strong corporate culture recognized at GeekWire Awards attracts top talent.
Funding
Total raised$395.75 M
Latest valuation$1.10 B
StageIPO
POST IPO DEBT
8/31/2022$125
SERIES F
4/30/2015$195
$1.10 BSERIES E
12/31/2014$94
$470.00 MSERIES C
3/31/2014$5
$25.00 MSERIES D
3/31/2014$100
$500.00 MGRANT
8/31/2013$2
SERIES B
5/31/2011$6
$29.00 MSERIES A
2/28/2010$5
$22.75 M